Complete Health Economics Outcomes and Research Solutions (CHEORS)

Industry / private company


Location: North Wales, PA, United States (USA) (US) US

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States (2023) Huang M, Fasching P, Haiderali A, Xue W, Yang C, Pan W, Zhou ZY, et al. Journal article Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1 (2022) Huang M, O'Shaughnessy J, Haiderali A, Pan W, Hu P, Chaudhuri M, Le Bailly De Tilleghem C, et al. Journal article Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer (2022) Huang M, Fasching P, Haiderali A, Pan W, Gray E, Zhou ZY, Hu P, et al. Journal article COST EFFECTIVENESS OF PEMBROLIZUMAB COMBINED WITH CHEMOTHERAPY VS. CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR METASTATIC TNBC THAT EXPRESSES PD-L1 IN THE UNITED STATES (2022) Huang M, Fasching P, Haiderali A, Pan W, Gray E, Zhou J, Hu PH, et al. Conference contribution Cost effectiveness of pembrolizumab in combination with chemotherapy as neoadjuvant therapy and continued as a single agent as adjuvant therapy for high-risk early-stage TNBC in the United States (2022) Fasching P, Huang M, Haiderali A, Xue W, Pan W, Zhou ZY, Hu P, et al. Conference contribution Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic TNBC that expresses PD-L1 (2022) Fasching P, Huang M, Haiderali A, Pan W, Hu P, Chaudhuri M, De Tilleghem CLB, et al. Conference contribution Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis (2020) Huang M, O'Shaughnessy J, Zhao J, Haiderali A, Cortes J, Ramsey SD, Briggs A, et al. Journal article, Review article